Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells

Dongshu Chen, Jianchuan Xia, Yasuhiro Tanaka, Hongsong Chen, Shigeo Koido, Oliver Wernet, Pinku Mukherjee, Sandra J Gendler, Donald Kufe, Jianlin Gong

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The tumour-associated antigen mucin 1 (MUC1) is a multifunctional protein involved in protection of mucous membranes, signal transduction, and modulation of the immune system. More than 70% of cancers overexpress MUC1, making MUC1 a potential target for immunotherapy. In the present study, MUC1 transgenic mice were crossed with syngeneic strains that express the polyomavirus middle-T oncogene (PyMT) driven by the mouse mammary tumour virus promoter long-terminal repeat (MMTV-LTR). The resultant breed (MMT mice) developed spontaneous MUC1-expressing mammary carcinomas with 100% penetrance at 8-15 weeks of age. As found in human breast cancer, the mammary carcinoma in MMT mice arose in multiple stages. Immunization with fusions of dendritic cells and MUC1-positive tumour cells (FC/MUC1) induced MUC1-specific immune responses that blocked or delayed the development of spontaneous breast carcinomas. In contrast, there was no delay of tumour development in MMT mice immunized with irradiated MC38/MUC1 tumour cells. The efficacy of fusion cells was closely correlated with the timing of initial immunization. Immunization with FC/MUC1 initiated in MMT mice at <1, 1-2 and 2-3 months of age rendered 33, 5 and 0% of mice free of tumour, respectively, up to 6 months. Whereas mice immunized in the later stage of tumour development succumbed to their disease, immunization resulted in control of tumour progression and prolongation of life. These results indicate that immunization with FC/MUC1 can generate an anti-MUC1 response that is sufficient to delay the development of spontaneous mammary carcinomas and control tumour progression in MMT mice.

Original languageEnglish (US)
Pages (from-to)300-307
Number of pages8
JournalImmunology
Volume109
Issue number2
DOIs
StatePublished - Jun 1 2003

Fingerprint

Mucin-1
Immunotherapy
Dendritic Cells
Breast Neoplasms
Carcinoma
Immunization
Neoplasms
Life Support Care
Mouse mammary tumor virus
Polyomavirus
Terminal Repeat Sequences
Penetrance
Cell Fusion
Neoplasm Antigens
Oncogenes
Carcinogens
Transgenic Mice
Immune System
Signal Transduction
Mucous Membrane

ASJC Scopus subject areas

  • Immunology

Cite this

Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. / Chen, Dongshu; Xia, Jianchuan; Tanaka, Yasuhiro; Chen, Hongsong; Koido, Shigeo; Wernet, Oliver; Mukherjee, Pinku; Gendler, Sandra J; Kufe, Donald; Gong, Jianlin.

In: Immunology, Vol. 109, No. 2, 01.06.2003, p. 300-307.

Research output: Contribution to journalArticle

Chen, D, Xia, J, Tanaka, Y, Chen, H, Koido, S, Wernet, O, Mukherjee, P, Gendler, SJ, Kufe, D & Gong, J 2003, 'Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells', Immunology, vol. 109, no. 2, pp. 300-307. https://doi.org/10.1046/j.1365-2567.2003.01656.x
Chen, Dongshu ; Xia, Jianchuan ; Tanaka, Yasuhiro ; Chen, Hongsong ; Koido, Shigeo ; Wernet, Oliver ; Mukherjee, Pinku ; Gendler, Sandra J ; Kufe, Donald ; Gong, Jianlin. / Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. In: Immunology. 2003 ; Vol. 109, No. 2. pp. 300-307.
@article{bd895d62dc3a49d295e70831a27cc795,
title = "Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells",
abstract = "The tumour-associated antigen mucin 1 (MUC1) is a multifunctional protein involved in protection of mucous membranes, signal transduction, and modulation of the immune system. More than 70{\%} of cancers overexpress MUC1, making MUC1 a potential target for immunotherapy. In the present study, MUC1 transgenic mice were crossed with syngeneic strains that express the polyomavirus middle-T oncogene (PyMT) driven by the mouse mammary tumour virus promoter long-terminal repeat (MMTV-LTR). The resultant breed (MMT mice) developed spontaneous MUC1-expressing mammary carcinomas with 100{\%} penetrance at 8-15 weeks of age. As found in human breast cancer, the mammary carcinoma in MMT mice arose in multiple stages. Immunization with fusions of dendritic cells and MUC1-positive tumour cells (FC/MUC1) induced MUC1-specific immune responses that blocked or delayed the development of spontaneous breast carcinomas. In contrast, there was no delay of tumour development in MMT mice immunized with irradiated MC38/MUC1 tumour cells. The efficacy of fusion cells was closely correlated with the timing of initial immunization. Immunization with FC/MUC1 initiated in MMT mice at <1, 1-2 and 2-3 months of age rendered 33, 5 and 0{\%} of mice free of tumour, respectively, up to 6 months. Whereas mice immunized in the later stage of tumour development succumbed to their disease, immunization resulted in control of tumour progression and prolongation of life. These results indicate that immunization with FC/MUC1 can generate an anti-MUC1 response that is sufficient to delay the development of spontaneous mammary carcinomas and control tumour progression in MMT mice.",
author = "Dongshu Chen and Jianchuan Xia and Yasuhiro Tanaka and Hongsong Chen and Shigeo Koido and Oliver Wernet and Pinku Mukherjee and Gendler, {Sandra J} and Donald Kufe and Jianlin Gong",
year = "2003",
month = "6",
day = "1",
doi = "10.1046/j.1365-2567.2003.01656.x",
language = "English (US)",
volume = "109",
pages = "300--307",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells

AU - Chen, Dongshu

AU - Xia, Jianchuan

AU - Tanaka, Yasuhiro

AU - Chen, Hongsong

AU - Koido, Shigeo

AU - Wernet, Oliver

AU - Mukherjee, Pinku

AU - Gendler, Sandra J

AU - Kufe, Donald

AU - Gong, Jianlin

PY - 2003/6/1

Y1 - 2003/6/1

N2 - The tumour-associated antigen mucin 1 (MUC1) is a multifunctional protein involved in protection of mucous membranes, signal transduction, and modulation of the immune system. More than 70% of cancers overexpress MUC1, making MUC1 a potential target for immunotherapy. In the present study, MUC1 transgenic mice were crossed with syngeneic strains that express the polyomavirus middle-T oncogene (PyMT) driven by the mouse mammary tumour virus promoter long-terminal repeat (MMTV-LTR). The resultant breed (MMT mice) developed spontaneous MUC1-expressing mammary carcinomas with 100% penetrance at 8-15 weeks of age. As found in human breast cancer, the mammary carcinoma in MMT mice arose in multiple stages. Immunization with fusions of dendritic cells and MUC1-positive tumour cells (FC/MUC1) induced MUC1-specific immune responses that blocked or delayed the development of spontaneous breast carcinomas. In contrast, there was no delay of tumour development in MMT mice immunized with irradiated MC38/MUC1 tumour cells. The efficacy of fusion cells was closely correlated with the timing of initial immunization. Immunization with FC/MUC1 initiated in MMT mice at <1, 1-2 and 2-3 months of age rendered 33, 5 and 0% of mice free of tumour, respectively, up to 6 months. Whereas mice immunized in the later stage of tumour development succumbed to their disease, immunization resulted in control of tumour progression and prolongation of life. These results indicate that immunization with FC/MUC1 can generate an anti-MUC1 response that is sufficient to delay the development of spontaneous mammary carcinomas and control tumour progression in MMT mice.

AB - The tumour-associated antigen mucin 1 (MUC1) is a multifunctional protein involved in protection of mucous membranes, signal transduction, and modulation of the immune system. More than 70% of cancers overexpress MUC1, making MUC1 a potential target for immunotherapy. In the present study, MUC1 transgenic mice were crossed with syngeneic strains that express the polyomavirus middle-T oncogene (PyMT) driven by the mouse mammary tumour virus promoter long-terminal repeat (MMTV-LTR). The resultant breed (MMT mice) developed spontaneous MUC1-expressing mammary carcinomas with 100% penetrance at 8-15 weeks of age. As found in human breast cancer, the mammary carcinoma in MMT mice arose in multiple stages. Immunization with fusions of dendritic cells and MUC1-positive tumour cells (FC/MUC1) induced MUC1-specific immune responses that blocked or delayed the development of spontaneous breast carcinomas. In contrast, there was no delay of tumour development in MMT mice immunized with irradiated MC38/MUC1 tumour cells. The efficacy of fusion cells was closely correlated with the timing of initial immunization. Immunization with FC/MUC1 initiated in MMT mice at <1, 1-2 and 2-3 months of age rendered 33, 5 and 0% of mice free of tumour, respectively, up to 6 months. Whereas mice immunized in the later stage of tumour development succumbed to their disease, immunization resulted in control of tumour progression and prolongation of life. These results indicate that immunization with FC/MUC1 can generate an anti-MUC1 response that is sufficient to delay the development of spontaneous mammary carcinomas and control tumour progression in MMT mice.

UR - http://www.scopus.com/inward/record.url?scp=0037843019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037843019&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2567.2003.01656.x

DO - 10.1046/j.1365-2567.2003.01656.x

M3 - Article

C2 - 12757626

AN - SCOPUS:0037843019

VL - 109

SP - 300

EP - 307

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 2

ER -